Search

Clinical trial enrollment of minorities, particularly Latinx and Black patients, lags behind that of the general population. Our Cancer Center is an NCI Community Oncology Research Program for Minority and Underserved populations (MU-NCORP) with 48% enrollment to interventional clinical trials from underrepresented minority populations. While above the national average, interventions are needed to address these gaps. The COVID-19 crisis highlighted inequities in health care for communities of color. In response to this, our department created a task force comprised of nurses, nurse practitioners, and research staff with the goal of addressing barriers that prevent underrepresented minorities from enrolling in clinical trials as well as compounding factors that contribute to poor health outcomes. In regards to clinical trial representation, additional efforts are needed to ensure underrepresented minorities are included in studies. Following major events in 2020, our staff expressed the need to contribute in a meaningful way by examining the gaps within our department and the cancer center as a whole. Our goals are to reduce implicit bias particularly when approaching patients about clinical trials, address socio-economic barriers impacting enrollment of diverse patients, and increase visibility of clinical trials. The task force developed a survey to assess the experience of patients and clinical trial discussions. Questions ask about logistical barriers, interpersonal provider relationships, and patient perceptions of discrimination. The data from these surveys will inform tailored patient education regarding clinical trials and guide clinicians in the best way to communicate clinical trial information. The team meets regularly to tackle adjacent issues associated with lack of inclusion. Strategies include enhanced racial and ethnic minority leadership recruitment, transparency in research findings, creating tools for the retention of clinical trial participants, and using social media to address misconceptions. Establishing a diversity, equity, and inclusion initiative empowered our staff to make concrete steps towards increased health equity. Our team has formed relationships with patient advocates and collaborated the community engagement office to continue working on changing the stigma of clinical trials through public education. Future projects include cultural competency training for staff, social media campaign for clinical trials awareness, and interpreting data from patient surveys to implement changes in clinical practice. [ABSTRACT FROM AUTHOR]